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OBJECTIVES: In the The Netherlands, a new drug is priced to the level of an existing 
drug cluster, if these are considered similar. However, when a drug is not considered 
similar to a cluster, a separate price can be requested. Before this separate price is 
approved, sufﬁ cient cost-effectiveness and budget impact (BI) data have to be provided 
to the Dutch Health Care Insurance Board (CVZ). The present analysis investigated 
how close the submitted BI-forecasts were to the actual BIs for cancer treatments in 
the The Netherlands. METHODS: The publicly available evaluations by the CVZ 
were assessed for cancer agents. From these, forecasted number of users, drug costs, 
treatment lengths, and the BIs were derived. The predicted BIs were compared with 
actual BIs from the GIP database (Dutch Drug Information System). The predicted BI 
was standardized with respect to time to ensure that actual and forecasted BIs shared 
the same starting point. Broadening of the indication was taken into account and 
substitution was considered. To further explain any difference in forecasted and actual 
BI, various variables such as drug cost, number of users, market share (when appli-
cable), and treatment lengths were investigated. RESULTS: The search provided ﬁ ve 
relevant cases. The forecasted budgets were lower than the actual ones in four out of 
the ﬁ ve cases. The forecasted and actual BI differed up to 250%. Data on drug sub-
stitution was insufﬁ cient and therefore not considered. The differences between pre-
dicted and observed BIs were explained primarily by an underestimation of the number 
of patients eventually receiving the evaluated treatments. The published BI forecasts 
contained no/very limited sensitivity analyses. CONCLUSIONS: Most BI forecasts 
underestimated the actual BI for new cancer drugs. One explanation was that the 
growth of the patient population was often underestimated. Improvements in predict-
ing total market size and penetration should be considered, as well as more elaborate 
sensitivity analysis.
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OBJECTIVES: Chemotherapy is standard choice as third-line treatment in patients 
with hormone-dependent metastatic breast cancer. The ﬁ eld research has shown that 
there is a need for additional hormonal drug in order to delay expensive and harmful 
chemotherapy. The aim is to analyze the impact on the budget Croatian Health Insur-
ance Institute (CHII) budget including the drug fulvestrant 250 mg on the basic drug 
list as a third-line treatment in patients with hormone-dependent metastatic breast 
cancer. METHODS: Markov model was used to develop a new treatment scenario. 
Program to calculate the ﬁ nancial impact on the budget was developed in Microsoft 
Excel. RESULTS: The scenario with fulvestrant given as a third line of treatment in 
a period of 4 months, followed by 4 months of paclitaxel, 3 months kapecitabine, 
and, ﬁ nally, 4 months with only supportive care was designed. This would delay the 
application of chemotherapy for an average of 4 months. Therefore, signiﬁ cantly fewer 
patients will be treated with chemotherapy. Additionally to that, a small part of 
patients would receive chemotherapy over a shorter period. The quality of life of 
metastatic breast cancer patients during their life expectancy would be signiﬁ cantly 
better, with the same expected survival rate and potentially lower cost of treatment. 
The impact budget analysis has shown reduce of therapy cost (4,202,922 Croatian 
Kuna or c579,713). CONCLUSIONS: A need for additional line of hormonal drug 
as a third-line treatment that can delay the implementation of poorly tolerated and 
expensive chemotherapy was established. The effectiveness of fulvestrant qualiﬁ ed it 
as a good candidate after the failure of the current endocrine therapy. The economic 
evaluation using Markov models and analysis of the budget impact in Croatia has 
been proven that adding fulvestrant in sequential treatment of metastatic breast cancer 
HR+ patients is cost-effective as third-line hormonal therapy in advanced breast 
cancer.
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OBJECTIVES: The aim of the analysis is to determine budget impact of reimbursement 
of capecitabine monotherapy used in the adjuvant therapy of patients after resection 
of stage III CC (Dukes’ C). METHODS: Cost data were collected from Polish public 
payer’s (National Health Fund) and patient’s perspectives and calculated for a 3-year 
time horizon. The population was estimated based on the Polish National Cancer 
Register. The following direct medical costs were included: cost of drugs used in 
adjuvant, I and II line chemotherapy, drug administration costs, adverse events, and 
monitoring costs. In “scenario A,” capecitabine was not reimbursed by the public 
payer, while the “scenario B” was developed under assumption of 100% capecitabine 
reimbursement. The proportion of patients treated with capecitabine and other drugs 
used in CC treatment was assessed based on the results of a questionnaire study 
conducted among Polish clinical experts. a cohort Markov model was used for simula-
tion of long-term health outcomes and costs. a range of variables was tested in one- 
and multi-way sensitivity analyses. RESULTS: “Scenario B” introduction led to 
savings equal to 24,730,000 PLN in the ﬁ rst year, 25,379,000 PLN in the second year, 
and 26,712,000 PLN in the third year from public payer’s perspective (1 EURO = 4.1 
PLN). Similarly, savings were observed when patient’s perspective was assumed. 
Results of sensitivity analysis conﬁ rmed conclusions from base-case analysis. CON-
CLUSIONS: One hundred percent reimbursement of capecitabine used in adjuvant 
therapy of patients after the resection for Dukes’ C CC leads to savings from both a 
public payer’s and patient’s perspectives in Poland.
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OBJECTIVES: Colorectal cancer is the second most common cancer in Spain (25,600 
incident cases and over 13,500 deaths yearly). Mutations in the KRAS oncogene are 
associated with a poor response to epidermal growth factor receptor (EGFR) inhibitor 
therapy in metastatic colorectal cancer (mCRC). In addition to avoiding unnecessary 
toxicity, implementing routine KRAS screening and limiting the use of EGFR inhibi-
tors to patients with wild-type KRAS may lead to cost savings. The objective is to 
estimate health and economic outcomes derived from carrying out KRAS determina-
tion in mCRC patients requiring an aggressive treatment in Spain. METHODS: 
Cost-effectiveness and budget impact analyses from national, regional, and hospital 
perspectives were developed in an interactive mode. Information was obtained from 
literature review of clinical trials (treatment response rates and prevalence of KRAS 
mutations), ofﬁ cial statistics (epidemiological data), and local databases (therapy and 
KRAS test costs). Multivariate sensitivity analysis can be performed by changing the 
technology for KRAS testing (PCR, real-time PCR), the chemotherapy regime 
(FOLFIRI, FOLFOX-4), and the proportion of wild-type patients to be treated with 
each therapy (bevacizumab, cetuximab). RESULTS: About 7000 mCRC patients will 
require an aggressive treatment in Spain in 2010. a strategy based on treating wild-type 
patients with cetuximab would raise ﬁ rst-line response rate from 44.80% to 53.84% 
(20.18%, 633 patients more) when combined with FOLFIRI (19.05%, 620 patients 
with FOLFOX-4) with an additional cost estimate of c22,117 per response (c17,201 
with FOLFOX-4). Budget impact of this approach amounts to a 9.06% (5.01% with 
FOLFOX-4) increase in resources devoted to mCRC treatment. Univariate and mul-
tivariate sensitivity analyses yield ratios between c19,101 and c27,531 and budget 
impact estimates of 0.16–9.16%. CONCLUSIONS: Treating wild-type KRAS mCRC 
patients with cetuximab would lead to over 600 additional patients (19–20%) with 
ﬁ rst-line response every year in Spain, with an associated budget impact of 9–11% of 
therapy cost.
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OBJECTIVES: Palonosetron is a 5-HT3 receptor antagonist (5-HT3-RA) indicated for 
the prevention and treatment of chemotherapy induced nausea and vomiting (CINV). 
Using an analytic model, this study explored the consequences of the restricted use of 
palonosetron for the treatment of CINV from a payer perspective. METHODS: The 
analytic model utilized rates of uncontrolled CINV among patients with cancer and 
initiated on palonosetron or another 5-HT3-RA for antiemetic prophylaxis. Other inputs 
included direct medical cost of a CINV event deﬁ ned by inpatient and outpatient visits, 
ﬁ xed Medicare reimbursement fees for medications (average sale price + 6%), national 
prescription utilization data, and the costs associated with executing a prior authoriza-
tion. Total costs associated with restricting palonosetron usage by 10% with a corre-
sponding 10% increase in generic 5-HT3-RA utilization were modeled for six cycles of 
moderately (MEC) and highly emetogenic chemotherapy (HEC). RESULTS: In a 1 
million member health plan, 15,000 patients (1.5%) were estimated to require che-
motherapy treatment annually. Of these, 10,800 patients (72%) were estimated to 
receive 5-HT3-RA prophylaxis on the ﬁ rst day of chemotherapy, with 7587 (51%) on 
either a MEC or HEC regimen. Result of the model demonstrated that a 10% reduc-
tion in palonosetron led to an overall savings in antiemetic costs equivalent to 
$762,616. However, total direct medical costs to the health plan (including the cost 
to treat uncontrolled CINV and the cost of the prior authorization program) increased 
by an estimated $865,457. Total cost of care, therefore, increased by an estimated 
$0.02 PMPM. CONCLUSIONS: Results from an analytic model showed that restrict-
ing palonosetron utilization by 10% through a prior authorization, while decreasing 
medication costs, produced an overall increase in total direct costs to the MCO. These 
results suggest that further studies on the clinical and economic impact of appropriate 
utilization of antiemetic prophylaxis for CINV are warranted.
